RxDoctor Payments Data

Maria Carpintero Ramirez, MD

Rheumatology · Miami, FLNPI 1134339443

Payments from drug & device makers

$352,640in general payments, 2019–2025

Across 71 payments — averaging $4966.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$69K
  • AbbVie$56K
  • Astrazeneca UK Limited$53K
  • GSK$47K
  • UCB SA$36K
  • Eli Lilly$23K
  • plus $68K from 6 others

What the payments were for

  • Food & beverage$435100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.6$68,883
AbbVie4$56,161
Astrazeneca UK Limited7$53,377
GSK16$47,168
UCB SA12$35,576
Eli Lilly2$23,435
Bristol Myers Squibb4$23,054
Janssen Research & Development, LLC9$22,443
Amgen2$14,764
Novartis6$7,463
Genentech USA, Inc.2$193
Bayer1$120

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$352,640 in reported general payments places this provider in the 85th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$29,698
Medicare patients
156
Services billed
291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab57$457,567
Enbrel SureclickEtanercept59$448,569
RinvoqUpadacitinib37$234,301
Humira PenAdalimumab28$188,849
Cosentyx Sensoready (2 Pens)Secukinumab24$177,042
BenlystaBelimumab33$153,245
Humira(Cf)Adalimumab22$149,855
Cimzia (2 Pack)Certolizumab Pegol15$83,041
Diclofenac Sodium262$14,412
RasuvoMethotrexate/Pf16$9,069
Mycophenolate Mofetil60$8,611
Hydroxychloroquine Sulfate444$8,526
MethotrexateMethotrexate Sodium342$4,077
Lidocaine20$3,509
Leflunomide52$2,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$56,161$384,15659 claims
GSKBenlysta$47,168$153,24533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →